Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Combinatorial Chemistry|May 13, 2003
Micro-X-ray fluorescence as a general high-throughput screening method for catalyst discovery and small molecule recognitionThomasin C Miller, Grace Mann, George J Havrilla, et al.
Breast Cancer Research and Treatment|November 21, 2018
Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutationsLynn Jongen, Giuseppe Floris, Bram Boeckx, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, NeratinibGary A Ulaner, Cristina Saura, Sarina A Piha-Paul, et al.
Head & Neck|October 9, 2021
Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinomaDavid M Cognetti, Jennifer M Johnson, Joseph M Curry, et al.
The Oncologist|August 27, 2024
Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT studyErkut H Borazanci, Nathan Bahary, Vincent Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIEMichele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2012
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitorsTimothy Forsyth, Patrick C Kearney, Byung Gyu Kim, et al.
Nature|February 14, 2019
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Nature|February 9, 2018
HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.
Cancer Discovery|December 7, 2019
Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast CancerLillian M Smyth, Sarina A Piha-Paul, Helen H Won, et al.
Pageof 1